| DB ID | MyCo_1790 |
| Title | Multiple experimental designs to evaluate the role of T-cell-mediated immunity against experimental vaginal Candida albicans infection |
| Year | 2003 |
| PMID | 14653516 |
| Fungal Diseases involved | Vulvovaginal candidiasis |
| Associated Medical Condition | None |
| Genus | Candida |
| Species | albicans |
| Organism | Candida albicans |
| Ethical Statement | Immunodeficient and ltnocltout mice were housed in a specific pathogen free facility and all animals were handled according to institutionally recommended guidelines, Louisiana State University Health Sciences Center; New Orleans, LA, USA. |
| Site of Infection | Vagina |
| Opportunistic invasive | Opportunistic |
| Sample type | Biopsy |
| Sample source | Homogenized tissue extracts |
| Host Group | Animal |
| Host Common name | Mice |
| Host Scientific name | Mus musculus |
| Biomarker Name | CD4 |
| Biomarker Full Name | CD4 |
| Biomarker Type | Negative |
| Biomolecule | Protein |
| Geographical Location | USA |
| Cohort | None |
| Cohort No. | None |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Vulvovaginal candidiasis (VVC) is an opportunistic mucosal infection that affects an estimated 75% of women at least once during their reproductive years. Candida albicans, a commensal fungal organism of the gastrointestinal and female genitourinary tracts, is the etiologic agent in 85-90% of all VVC cases. Although most women experience sporadic episodes of acute VVC, 5-10% of otherwise healthy women, without any recognizable predisposing factors (i.e. antibiotic therapy, uncontrolled diabetes mellitus, hormone replacement therapy, contraceptive usage or pregnancy), suffer from recurrent VVC (RVVC), which is defined as more than three episodes per year. Antifungal therapy is effective in resolving individual symptomatic episodes of VVC but does not prevent recurrence. There is little evidence that antifungal drug resistance contributes to the recurrent nature of RVVC pathogenesis, suggesting that susceptibility may result from some immunological dysfunction or deficiency. |
| Technique | ELISA |
| Analysis Method | ELISA Based |
| ELISA kits | Colorimetric protein assay kit (Pierce, Rockford, IL, USA), Mouse OptELA ELISA KIT (BD PharMingen, San Diego, CA, USA), Human TGF-ß1 DuoSet ELISA system (Genzyme Diagnostics, Cambridge MA, USA), mouse TGF-ß I (Genzyme Diagnostics) |
| Assay Data | None |
| Validation Techniques used | ELISA |
| Up Regulation Down Regulation | None |
| Sequence Data | None |
| External Link | None |
